Shares of struggling drug developer Sarepta Therapeutics skyrocketed nearly 40% in extended trading Wednesday after the company unveiled a major restructuring plan.

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...